2018 Asembia Recap

Challenges in Treating Idiopathic Pulmonary Fibrosis

June 25, 2018

CE Highlights

Idiopathic pulmonary fibrosis (IPF) remains difficult to diagnose and manage because of its unknown etiology, varied clinical course, associated comorbidities, and nonspecific respiratory symptoms.

The Future of Treating Psoriatic Disease

June 25, 2018

CE Highlights

The number of treatment options available for psoriasis (PsO) and psoriatic arthritis (PsA) has significantly increased in the past decade and can provide patients with multiple modalities for efficacious symptom treatment, according to a continuing education symposium presented at the Asembia Specialty Pharmacy Summit 2018.

The Evolution of Immunoglobulin Therapy

June 25, 2018

CE Highlights

This symposium traced the evolution of immunoglobulin therapy from this inception to the state-of-the-art intravenous immunoglobulin products currently employed to manage a wide range of immune disorders.

Novel Therapies in Rheumatoid Arthritis

June 25, 2018

CE Highlights

A symposium presented at the Asembia Specialty Pharmacy Summit 2018 provided pharmacists a review of guideline-based RA management strategies, along with recent trial data on new and emerging agents.

Asembia Featured Session Highlights Factors That Will Influence the Future of Specialty Pharmacy

June 22, 2018

Features

Caught in the middle of a maelstrom of change currently engulfing the health care industry, specialty pharmacy is emerging as a powerful force that will play a key role in the growing conversations regarding value in health care.

Value Takes Center Stage at Asembia

June 21, 2018

From the Chairman

As industry leaders converged on the largest annual conference focused on specialty pharmacy, issues surrounding value dominated the conversations at the Asembia Specialty Pharmacy Summit 2018.